Carfilzomib combined with suberanilohydroxamic acid (SAHA) synergistically promotes endoplasmic reticulum stress in non-small cell lung cancer cell lines View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2015-09-18

AUTHORS

Neale T. Hanke, Linda L. Garland, Amanda F. Baker

ABSTRACT

PurposeThe endoplasmic reticulum (ER) stress response is a therapeutic target for pharmacologic intervention in cancer cells. We hypothesized that combining carfilzomib (CFZ), a proteasome inhibitor, and vorinostat (SAHA), a histone deacetylase (HDAC) inhibitor, would synergistically activate ER stress in non-small cell lung cancer (NSCLC) cell lines, resulting in enhanced anti-tumor activity.MethodsFive NSCLC cell lines were treated with CFZ, SAHA, or the combination and cell proliferation measured using the MTT assay. Calcusyn software was utilized to determine the combination index as a measure of synergy. Cell viability and cytotoxicity were measured using trypan blue exclusion, CellTiter, and CytoTox assays. Western blot was used to measure markers of apoptosis, ER stress, and oxidative stress-related proteins. Reactive oxygen species (ROS) was measured using the fluorophore CM–H2DCFDA.ResultsSynergistic activity was observed for all cell lines following 48 and 72 h of combined treatment. H520 and A549 cell lines were used to assess viability and apoptosis. In both cell lines, increased death and cleaved caspase-3 were observed following combination treatment as compared with single-agent treatments. Combination therapy was associated with upregulation of ER stress-regulated proteins including activating transcription factor 4, GRP78/BiP, and C/EBP homologous protein. Both cell lines also showed increased ROS and the oxidative stress-related protein, heat shock protein 70.ConclusionCombining proteasome inhibition with HDAC inhibition enhances ER stress, which may contribute to the synergistic anticancer activity observed in NSCLC cell lines. Further preclinical and clinical studies of CFZ + SAHA in NSCLC are warranted. More... »

PAGES

549-560

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00432-015-2047-6

DOI

http://dx.doi.org/10.1007/s00432-015-2047-6

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1052308469

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/26385374


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Apoptosis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Carcinoma, Non-Small-Cell Lung", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cell Line, Tumor", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cell Proliferation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cell Survival", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Dose-Response Relationship, Drug", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Synergism", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Endoplasmic Reticulum Stress", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Histone Deacetylase Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hydroxamic Acids", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lung Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Oligopeptides", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Oxidative Stress", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Vorinostat", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Section of Hematology/Oncology, College of Medicine, University of Arizona Cancer Center, 1515 N Campbell Ave, Tucson, AZ, USA", 
          "id": "http://www.grid.ac/institutes/grid.134563.6", 
          "name": [
            "Section of Hematology/Oncology, College of Medicine, University of Arizona Cancer Center, 1515 N Campbell Ave, Tucson, AZ, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hanke", 
        "givenName": "Neale T.", 
        "id": "sg:person.01231024471.66", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01231024471.66"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Section of Hematology/Oncology, College of Medicine, University of Arizona Cancer Center, 1515 N Campbell Ave, Tucson, AZ, USA", 
          "id": "http://www.grid.ac/institutes/grid.134563.6", 
          "name": [
            "Section of Hematology/Oncology, College of Medicine, University of Arizona Cancer Center, 1515 N Campbell Ave, Tucson, AZ, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Garland", 
        "givenName": "Linda L.", 
        "id": "sg:person.01322145005.35", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01322145005.35"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Section of Hematology/Oncology, College of Medicine, University of Arizona Cancer Center, 1515 N Campbell Ave, Tucson, AZ, USA", 
          "id": "http://www.grid.ac/institutes/grid.134563.6", 
          "name": [
            "Section of Hematology/Oncology, College of Medicine, University of Arizona Cancer Center, 1515 N Campbell Ave, Tucson, AZ, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Baker", 
        "givenName": "Amanda F.", 
        "id": "sg:person.01067534552.92", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01067534552.92"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s10637-013-9980-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043386127", 
          "https://doi.org/10.1007/s10637-013-9980-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrd2133", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023003326", 
          "https://doi.org/10.1038/nrd2133"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s13046-014-0111-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015832532", 
          "https://doi.org/10.1186/s13046-014-0111-8"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2015-09-18", 
    "datePublishedReg": "2015-09-18", 
    "description": "PurposeThe endoplasmic reticulum (ER) stress response is a therapeutic target for pharmacologic intervention in cancer cells. We hypothesized that combining carfilzomib (CFZ), a proteasome inhibitor, and vorinostat (SAHA), a histone deacetylase (HDAC) inhibitor, would synergistically activate ER stress in non-small cell lung cancer (NSCLC) cell lines, resulting in enhanced anti-tumor activity.MethodsFive NSCLC cell lines were treated with CFZ, SAHA, or the combination and cell proliferation measured using the MTT assay. Calcusyn software was utilized to determine the combination index as a measure of synergy. Cell viability and cytotoxicity were measured using trypan blue exclusion, CellTiter, and CytoTox assays. Western blot was used to measure markers of apoptosis, ER stress, and oxidative stress-related proteins. Reactive oxygen species (ROS) was measured using the fluorophore CM\u2013H2DCFDA.ResultsSynergistic activity was observed for all cell lines following 48 and 72\u00a0h of combined treatment. H520 and A549 cell lines were used to assess viability and apoptosis. In both cell lines, increased death and cleaved caspase-3 were observed following combination treatment as compared with single-agent treatments. Combination therapy was associated with upregulation of ER stress-regulated proteins including activating transcription factor 4, GRP78/BiP, and C/EBP homologous protein. Both cell lines also showed increased ROS and the oxidative stress-related protein, heat shock protein 70.ConclusionCombining proteasome inhibition with HDAC inhibition enhances ER stress, which may contribute to the synergistic anticancer activity observed in NSCLC cell lines. Further preclinical and clinical studies of CFZ\u00a0+\u00a0SAHA in NSCLC are warranted.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s00432-015-2047-6", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.2438836", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1313647", 
        "issn": [
          "0171-5216", 
          "1432-1335"
        ], 
        "name": "Journal of Cancer Research and Clinical Oncology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "3", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "142"
      }
    ], 
    "keywords": [
      "non-small cell lung cancer cell lines", 
      "cell lung cancer cell lines", 
      "lung cancer cell lines", 
      "NSCLC cell lines", 
      "suberanilohydroxamic acid", 
      "cancer cell lines", 
      "oxidative stress-related proteins", 
      "reactive oxygen species", 
      "cell lines", 
      "ER stress", 
      "stress-related proteins", 
      "single-agent treatment", 
      "enhanced anti-tumor activity", 
      "anti-tumor activity", 
      "histone deacetylase inhibitors", 
      "EBP homologous protein", 
      "trypan blue exclusion", 
      "synergistic anticancer activity", 
      "markers of apoptosis", 
      "endoplasmic reticulum stress response", 
      "endoplasmic reticulum stress", 
      "pharmacologic interventions", 
      "combination therapy", 
      "CalcuSyn software", 
      "clinical studies", 
      "transcription factor 4", 
      "combination treatment", 
      "therapeutic target", 
      "carfilzomib", 
      "deacetylase inhibitors", 
      "HDAC inhibition", 
      "GRP78/BiP", 
      "Western blot", 
      "combination index", 
      "A549 cell line", 
      "stress-regulated proteins", 
      "blue exclusion", 
      "reticulum stress", 
      "cancer cells", 
      "proteasome inhibitors", 
      "CM-H2DCFDA", 
      "cell proliferation", 
      "MTT assay", 
      "caspase-3", 
      "factor 4", 
      "cell viability", 
      "treatment", 
      "anticancer activity", 
      "homologous proteins", 
      "oxygen species", 
      "stress response", 
      "apoptosis", 
      "inhibitors", 
      "inhibition", 
      "protein", 
      "assays", 
      "NSCLC", 
      "vorinostat", 
      "therapy", 
      "H520", 
      "activity", 
      "upregulation", 
      "death", 
      "intervention", 
      "blot", 
      "viability", 
      "proliferation", 
      "markers", 
      "measure of synergy", 
      "cytotoxicity", 
      "CellTiter", 
      "cells", 
      "stress", 
      "lines", 
      "BiP", 
      "species", 
      "response", 
      "index", 
      "target", 
      "study", 
      "measures", 
      "exclusion", 
      "acid", 
      "combination", 
      "synergy", 
      "software", 
      "PurposeThe endoplasmic reticulum (ER) stress response", 
      "reticulum (ER) stress response", 
      "MethodsFive NSCLC cell lines", 
      "CytoTox assays", 
      "fluorophore CM\u2013H2DCFDA", 
      "ResultsSynergistic activity", 
      "ER stress-regulated proteins"
    ], 
    "name": "Carfilzomib combined with suberanilohydroxamic acid (SAHA) synergistically promotes endoplasmic reticulum stress in non-small cell lung cancer cell lines", 
    "pagination": "549-560", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1052308469"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00432-015-2047-6"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "26385374"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00432-015-2047-6", 
      "https://app.dimensions.ai/details/publication/pub.1052308469"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-01-01T18:36", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220101/entities/gbq_results/article/article_662.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s00432-015-2047-6"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00432-015-2047-6'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00432-015-2047-6'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00432-015-2047-6'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00432-015-2047-6'


 

This table displays all metadata directly associated to this object as RDF triples.

243 TRIPLES      22 PREDICATES      137 URIs      126 LITERALS      22 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00432-015-2047-6 schema:about N0585457d95864b1e8061edd3d359c1f9
2 N13b0e30369ee4ffca8030b079db6273e
3 N177c5e2321b6462ba6f1ddd17ed091f8
4 N2374c57845b24cbdaa016530868acd55
5 N2835426a138c4faca177868eb9629af5
6 N3619bc149d03480794d942e6d2856513
7 N41178a8442394c3bb559b5c5874888d2
8 N495fdd5c24744c4699e2e959b81eaa8d
9 N793b1b7aac324d11b8180b801ac188df
10 N8a983d135ce5443fa8b01125a4bc1369
11 Nb8f2a709702547dc86474647ea520b2c
12 Nb9fb5262141447748528b2d729f93bf7
13 Nbd4171939ffc4d68be8925c2c65277dc
14 Ncfa42b44e2c940168f582a20d85b5d39
15 Ne4affd85a486489ba3b00c590df68f87
16 anzsrc-for:11
17 anzsrc-for:1112
18 schema:author N599f8c58efb54a6fb91710aeb14636fe
19 schema:citation sg:pub.10.1007/s10637-013-9980-5
20 sg:pub.10.1038/nrd2133
21 sg:pub.10.1186/s13046-014-0111-8
22 schema:datePublished 2015-09-18
23 schema:datePublishedReg 2015-09-18
24 schema:description PurposeThe endoplasmic reticulum (ER) stress response is a therapeutic target for pharmacologic intervention in cancer cells. We hypothesized that combining carfilzomib (CFZ), a proteasome inhibitor, and vorinostat (SAHA), a histone deacetylase (HDAC) inhibitor, would synergistically activate ER stress in non-small cell lung cancer (NSCLC) cell lines, resulting in enhanced anti-tumor activity.MethodsFive NSCLC cell lines were treated with CFZ, SAHA, or the combination and cell proliferation measured using the MTT assay. Calcusyn software was utilized to determine the combination index as a measure of synergy. Cell viability and cytotoxicity were measured using trypan blue exclusion, CellTiter, and CytoTox assays. Western blot was used to measure markers of apoptosis, ER stress, and oxidative stress-related proteins. Reactive oxygen species (ROS) was measured using the fluorophore CM–H2DCFDA.ResultsSynergistic activity was observed for all cell lines following 48 and 72 h of combined treatment. H520 and A549 cell lines were used to assess viability and apoptosis. In both cell lines, increased death and cleaved caspase-3 were observed following combination treatment as compared with single-agent treatments. Combination therapy was associated with upregulation of ER stress-regulated proteins including activating transcription factor 4, GRP78/BiP, and C/EBP homologous protein. Both cell lines also showed increased ROS and the oxidative stress-related protein, heat shock protein 70.ConclusionCombining proteasome inhibition with HDAC inhibition enhances ER stress, which may contribute to the synergistic anticancer activity observed in NSCLC cell lines. Further preclinical and clinical studies of CFZ + SAHA in NSCLC are warranted.
25 schema:genre article
26 schema:inLanguage en
27 schema:isAccessibleForFree true
28 schema:isPartOf N4a3cd09b20c341ac8f67810937a343e3
29 N633dd7a10b914b668fad0dd9d54fe10e
30 sg:journal.1313647
31 schema:keywords A549 cell line
32 BiP
33 CM-H2DCFDA
34 CalcuSyn software
35 CellTiter
36 CytoTox assays
37 EBP homologous protein
38 ER stress
39 ER stress-regulated proteins
40 GRP78/BiP
41 H520
42 HDAC inhibition
43 MTT assay
44 MethodsFive NSCLC cell lines
45 NSCLC
46 NSCLC cell lines
47 PurposeThe endoplasmic reticulum (ER) stress response
48 ResultsSynergistic activity
49 Western blot
50 acid
51 activity
52 anti-tumor activity
53 anticancer activity
54 apoptosis
55 assays
56 blot
57 blue exclusion
58 cancer cell lines
59 cancer cells
60 carfilzomib
61 caspase-3
62 cell lines
63 cell lung cancer cell lines
64 cell proliferation
65 cell viability
66 cells
67 clinical studies
68 combination
69 combination index
70 combination therapy
71 combination treatment
72 cytotoxicity
73 deacetylase inhibitors
74 death
75 endoplasmic reticulum stress
76 endoplasmic reticulum stress response
77 enhanced anti-tumor activity
78 exclusion
79 factor 4
80 fluorophore CM–H2DCFDA
81 histone deacetylase inhibitors
82 homologous proteins
83 index
84 inhibition
85 inhibitors
86 intervention
87 lines
88 lung cancer cell lines
89 markers
90 markers of apoptosis
91 measure of synergy
92 measures
93 non-small cell lung cancer cell lines
94 oxidative stress-related proteins
95 oxygen species
96 pharmacologic interventions
97 proliferation
98 proteasome inhibitors
99 protein
100 reactive oxygen species
101 response
102 reticulum (ER) stress response
103 reticulum stress
104 single-agent treatment
105 software
106 species
107 stress
108 stress response
109 stress-regulated proteins
110 stress-related proteins
111 study
112 suberanilohydroxamic acid
113 synergistic anticancer activity
114 synergy
115 target
116 therapeutic target
117 therapy
118 transcription factor 4
119 treatment
120 trypan blue exclusion
121 upregulation
122 viability
123 vorinostat
124 schema:name Carfilzomib combined with suberanilohydroxamic acid (SAHA) synergistically promotes endoplasmic reticulum stress in non-small cell lung cancer cell lines
125 schema:pagination 549-560
126 schema:productId N76782c4f41214a7a960b57680df4a598
127 N858e5760960b4c8da1ae20773190237b
128 Nc4b6a3fe64fa403ab8839f69b766cfb1
129 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052308469
130 https://doi.org/10.1007/s00432-015-2047-6
131 schema:sdDatePublished 2022-01-01T18:36
132 schema:sdLicense https://scigraph.springernature.com/explorer/license/
133 schema:sdPublisher N0bacd1c1f8054c88928d47eee9cd8fea
134 schema:url https://doi.org/10.1007/s00432-015-2047-6
135 sgo:license sg:explorer/license/
136 sgo:sdDataset articles
137 rdf:type schema:ScholarlyArticle
138 N0585457d95864b1e8061edd3d359c1f9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Cell Proliferation
140 rdf:type schema:DefinedTerm
141 N0ba46232b1614f7eac972a3b61d7fba1 rdf:first sg:person.01067534552.92
142 rdf:rest rdf:nil
143 N0bacd1c1f8054c88928d47eee9cd8fea schema:name Springer Nature - SN SciGraph project
144 rdf:type schema:Organization
145 N13b0e30369ee4ffca8030b079db6273e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
146 schema:name Humans
147 rdf:type schema:DefinedTerm
148 N177c5e2321b6462ba6f1ddd17ed091f8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
149 schema:name Endoplasmic Reticulum Stress
150 rdf:type schema:DefinedTerm
151 N2374c57845b24cbdaa016530868acd55 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Oligopeptides
153 rdf:type schema:DefinedTerm
154 N2835426a138c4faca177868eb9629af5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name Carcinoma, Non-Small-Cell Lung
156 rdf:type schema:DefinedTerm
157 N3619bc149d03480794d942e6d2856513 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
158 schema:name Histone Deacetylase Inhibitors
159 rdf:type schema:DefinedTerm
160 N41178a8442394c3bb559b5c5874888d2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
161 schema:name Oxidative Stress
162 rdf:type schema:DefinedTerm
163 N495fdd5c24744c4699e2e959b81eaa8d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
164 schema:name Cell Survival
165 rdf:type schema:DefinedTerm
166 N4a3cd09b20c341ac8f67810937a343e3 schema:issueNumber 3
167 rdf:type schema:PublicationIssue
168 N599f8c58efb54a6fb91710aeb14636fe rdf:first sg:person.01231024471.66
169 rdf:rest Nad2d2459beb04d31834b15f0c711175f
170 N633dd7a10b914b668fad0dd9d54fe10e schema:volumeNumber 142
171 rdf:type schema:PublicationVolume
172 N76782c4f41214a7a960b57680df4a598 schema:name dimensions_id
173 schema:value pub.1052308469
174 rdf:type schema:PropertyValue
175 N793b1b7aac324d11b8180b801ac188df schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
176 schema:name Lung Neoplasms
177 rdf:type schema:DefinedTerm
178 N858e5760960b4c8da1ae20773190237b schema:name doi
179 schema:value 10.1007/s00432-015-2047-6
180 rdf:type schema:PropertyValue
181 N8a983d135ce5443fa8b01125a4bc1369 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
182 schema:name Dose-Response Relationship, Drug
183 rdf:type schema:DefinedTerm
184 Nad2d2459beb04d31834b15f0c711175f rdf:first sg:person.01322145005.35
185 rdf:rest N0ba46232b1614f7eac972a3b61d7fba1
186 Nb8f2a709702547dc86474647ea520b2c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
187 schema:name Hydroxamic Acids
188 rdf:type schema:DefinedTerm
189 Nb9fb5262141447748528b2d729f93bf7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
190 schema:name Apoptosis
191 rdf:type schema:DefinedTerm
192 Nbd4171939ffc4d68be8925c2c65277dc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
193 schema:name Cell Line, Tumor
194 rdf:type schema:DefinedTerm
195 Nc4b6a3fe64fa403ab8839f69b766cfb1 schema:name pubmed_id
196 schema:value 26385374
197 rdf:type schema:PropertyValue
198 Ncfa42b44e2c940168f582a20d85b5d39 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
199 schema:name Drug Synergism
200 rdf:type schema:DefinedTerm
201 Ne4affd85a486489ba3b00c590df68f87 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
202 schema:name Vorinostat
203 rdf:type schema:DefinedTerm
204 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
205 schema:name Medical and Health Sciences
206 rdf:type schema:DefinedTerm
207 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
208 schema:name Oncology and Carcinogenesis
209 rdf:type schema:DefinedTerm
210 sg:grant.2438836 http://pending.schema.org/fundedItem sg:pub.10.1007/s00432-015-2047-6
211 rdf:type schema:MonetaryGrant
212 sg:journal.1313647 schema:issn 0171-5216
213 1432-1335
214 schema:name Journal of Cancer Research and Clinical Oncology
215 schema:publisher Springer Nature
216 rdf:type schema:Periodical
217 sg:person.01067534552.92 schema:affiliation grid-institutes:grid.134563.6
218 schema:familyName Baker
219 schema:givenName Amanda F.
220 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01067534552.92
221 rdf:type schema:Person
222 sg:person.01231024471.66 schema:affiliation grid-institutes:grid.134563.6
223 schema:familyName Hanke
224 schema:givenName Neale T.
225 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01231024471.66
226 rdf:type schema:Person
227 sg:person.01322145005.35 schema:affiliation grid-institutes:grid.134563.6
228 schema:familyName Garland
229 schema:givenName Linda L.
230 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01322145005.35
231 rdf:type schema:Person
232 sg:pub.10.1007/s10637-013-9980-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043386127
233 https://doi.org/10.1007/s10637-013-9980-5
234 rdf:type schema:CreativeWork
235 sg:pub.10.1038/nrd2133 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023003326
236 https://doi.org/10.1038/nrd2133
237 rdf:type schema:CreativeWork
238 sg:pub.10.1186/s13046-014-0111-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015832532
239 https://doi.org/10.1186/s13046-014-0111-8
240 rdf:type schema:CreativeWork
241 grid-institutes:grid.134563.6 schema:alternateName Section of Hematology/Oncology, College of Medicine, University of Arizona Cancer Center, 1515 N Campbell Ave, Tucson, AZ, USA
242 schema:name Section of Hematology/Oncology, College of Medicine, University of Arizona Cancer Center, 1515 N Campbell Ave, Tucson, AZ, USA
243 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...